Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 430

1.

Screening for elevated albuminuria and subsequently hypertension identifies subjects in which treatment may be warranted to prevent renal function decline.

Özyilmaz A, de Jong PE, Bakker SJL, Visser ST, Thio C, Gansevoort RT; PREVEND Study Group.

Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii200-ii208. doi: 10.1093/ndt/gfw414.

PMID:
28031343
2.

Past Decline Versus Current eGFR and Subsequent Mortality Risk.

Naimark DM, Grams ME, Matsushita K, Black C, Drion I, Fox CS, Inker LA, Ishani A, Jee SH, Kitamura A, Lea JP, Nally J, Peralta CA, Rothenbacher D, Ryu S, Tonelli M, Yatsuya H, Coresh J, Gansevoort RT, Warnock DG, Woodward M, de Jong PE; CKD Prognosis Consortium.

J Am Soc Nephrol. 2016 Aug;27(8):2456-66. doi: 10.1681/ASN.2015060688. Epub 2015 Dec 11.

3.

The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.

Özyilmaz A, Boersma C, Visser ST, Postma MJ, de Jong-van den Berg LT, Lambers-Heerspink HJ, de Jong PE, Gansevoort RT.

Eur J Prev Cardiol. 2016 May;23(8):847-55. doi: 10.1177/2047487315604310. Epub 2015 Sep 10.

PMID:
26358992
4.

Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study.

Vart P, Scheven L, Lambers Heerspink HJ, de Jong PE, de Zeeuw D, Gansevoort RT; PREVEND Study Group and the RENAAL Investigators.

Am J Kidney Dis. 2016 Jan;67(1):70-8. doi: 10.1053/j.ajkd.2015.05.025. Epub 2015 Jul 15.

PMID:
26188433
5.

Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease.

Spithoven EM, Meijer E, Borns C, Boertien WE, Gaillard CA, Kappert P, Greuter MJ, van der Jagt E, Vart P, de Jong PE, Gansevoort RT.

Eur Radiol. 2016 Mar;26(3):683-92. doi: 10.1007/s00330-015-3877-y. Epub 2015 Jul 11.

6.

[The prevention of renal failure has to improve].

Gansevoort RT, Lambers Heerspink HJ, de Jong PE.

Ned Tijdschr Geneeskd. 2015;159:A8472. Dutch.

PMID:
25690073
7.

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.

Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.

PMID:
25600953
8.

Effect of nocturnal haemodialysis on body composition.

Ipema KJ, Westerhuis R, van der Schans CP, de Jong PE, Gaillard CA, Krijnen WP, Slart RH, Franssen CF.

Nephron Clin Pract. 2014;128(1-2):171-7. doi: 10.1159/000368239. Epub 2014 Nov 6.

PMID:
25376526
9.

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1553-62. doi: 10.2215/CJN.08690813. Epub 2014 Jul 3.

10.

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.

Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS.

JAMA. 2014 Jun 25;311(24):2518-2531. doi: 10.1001/jama.2014.6634.

11.

The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort.

Scheven L, Joosten MM, de Jong PE, Bakker SJ, Gansevoort RT; PREVEND study group.

J Am Heart Assoc. 2014;3(2):e000613.

12.

Dialysis hypotension: a role for inadequate increase in arginine vasopressin levels? A systematic literature review and meta-analysis.

Ettema EM, Zittema D, Kuipers J, Gansevoort RT, Vart P, de Jong PE, Westerhuis R, Franssen CF.

Am J Nephrol. 2014;39(2):100-9. doi: 10.1159/000358203. Epub 2014 Feb 6. Review.

13.

Hemodialysis-induced regional left ventricular systolic dysfunction and inflammation: a cross-sectional study.

Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, Groen H, Bakker SJ, Muller Kobold AC, van Oeveren W, Struck J, de Jong PE, Franssen CF.

Am J Kidney Dis. 2014 Aug;64(2):265-73. doi: 10.1053/j.ajkd.2013.11.010. Epub 2013 Dec 21.

PMID:
24364893
14.

Telomere length loss due to smoking and metabolic traits.

Huzen J, Wong LS, van Veldhuisen DJ, Samani NJ, Zwinderman AH, Codd V, Cawthon RM, Benus GF, van der Horst IC, Navis G, Bakker SJ, Gansevoort RT, de Jong PE, Hillege HL, van Gilst WH, de Boer RA, van der Harst P.

J Intern Med. 2014 Feb;275(2):155-63. doi: 10.1111/joim.12149. Epub 2013 Nov 5.

15.

Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events.

Özyilmaz A, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group.

Nephrol Dial Transplant. 2013 Nov;28(11):2805-15. doi: 10.1093/ndt/gft254. Epub 2013 Aug 23.

PMID:
23975751
16.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.

Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

17.

Stability of creatinine and cystatin C in whole blood.

Spithoven EM, Bakker SJ, Kootstra-Ros JE, de Jong PE, Gansevoort RT; DIPAK Consortium Investigators.

Clin Biochem. 2013 Oct;46(15):1611-4. doi: 10.1016/j.clinbiochem.2013.06.022. Epub 2013 Jul 2.

PMID:
23830842
18.

Variability of predialytic, intradialytic, and postdialytic blood pressures in the course of a week: a study of Dutch and US maintenance hemodialysis patients.

Kuipers J, Usvyat LA, Oosterhuis JK, Dasselaar JJ, de Jong PE, Westerhuis R, Sands JJ, Wang Y, Kotanko P, Franssen CF.

Am J Kidney Dis. 2013 Oct;62(4):779-88. doi: 10.1053/j.ajkd.2013.03.034. Epub 2013 Jun 4.

PMID:
23759298
19.

Twenty-four hour urinary urea excretion and 9-year risk of hypertension: the PREVEND study.

Tielemans SM, Geleijnse JM, van Baak MA, Engberink MF, Brink EJ, de Jong PE, Gansevoort RT, Bakker SJ; PREVEND Study Group.

J Hypertens. 2013 Aug;31(8):1564-9. doi: 10.1097/HJH.0b013e328362213b.

PMID:
23751964
20.

Predictors of progression in albuminuria in the general population: results from the PREVEND cohort.

Scheven L, Halbesma N, de Jong PE, de Zeeuw D, Bakker SJ, Gansevoort RT.

PLoS One. 2013 May 27;8(5):e61119. doi: 10.1371/journal.pone.0061119. Print 2013.

21.

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT.

Am J Kidney Dis. 2013 Sep;62(3):531-40. doi: 10.1053/j.ajkd.2013.03.030. Epub 2013 May 25.

PMID:
23714171
22.

Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT.

Diabetologia. 2013 Aug;56(8):1680-8. doi: 10.1007/s00125-013-2922-0. Epub 2013 Apr 28.

PMID:
23624546
23.

Changes in left ventricular diastolic function during hemodialysis sessions.

Assa S, Hummel YM, Voors AA, Kuipers J, Groen H, de Jong PE, Westerhuis R, Franssen CF.

Am J Kidney Dis. 2013 Sep;62(3):549-56. doi: 10.1053/j.ajkd.2013.02.356. Epub 2013 Mar 30.

PMID:
23548554
24.

Glomerular and tubular damage markers in individuals with progressive albuminuria.

Nauta FL, Scheven L, Meijer E, van Oeveren W, de Jong PE, Bakker SJ, Gansevoort RT.

Clin J Am Soc Nephrol. 2013 Jul;8(7):1106-14. doi: 10.2215/CJN.04510512. Epub 2013 Mar 28.

25.

Isolated microalbuminuria indicates a poor medical prognosis.

Scheven L, Van der Velde M, Lambers Heerspink HJ, De Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2013 Jul;28(7):1794-801. doi: 10.1093/ndt/gft031. Epub 2013 Mar 13.

PMID:
23493327
26.

Determinants and prognostic significance of an intra-dialysis rise of cardiac troponin I measured by sensitive assay in hemodialysis patients.

Assa S, Gansevoort RT, Westerhuis R, Kobold AC, Voors AA, de Jong PE, Bakker SJ, Franssen CF.

Clin Res Cardiol. 2013 Jun;102(6):439-45. doi: 10.1007/s00392-013-0551-8. Epub 2013 Feb 9.

PMID:
23397594
27.

Change in the estimated glomerular filtration rate over time and risk of all-cause mortality.

Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR.

Kidney Int. 2013 Apr;83(4):684-91. doi: 10.1038/ki.2012.443. Epub 2013 Jan 23.

28.

Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality.

Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Schulte J, Hillege HL, van der Harst P, Peelen LM, Beulens JW, Stolk RP, Navis G, Bakker SJ.

J Am Heart Assoc. 2012 Oct;1(5):e002956. doi: 10.1161/JAHA.112.002956. Epub 2012 Oct 25.

29.

Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage.

Özyilmaz A, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Nov;27(11):4046-52. doi: 10.1093/ndt/gfs438. Review.

PMID:
23144071
30.

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium.

Lancet. 2012 Nov 10;380(9854):1662-73. doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24. Review. Erratum in: Lancet. 2013 Feb 2;381(9864):374.

31.

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC; Chronic Kidney Disease Prognosis Consortium.

Lancet. 2012 Nov 10;380(9854):1649-61. doi: 10.1016/S0140-6736(12)61272-0. Epub 2012 Sep 24. Review. Erratum in: Lancet. 2012 Nov 10;380(9854):1648.

32.

Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study.

Smink PA, Lambers Heerspink HJ, Gansevoort RT, de Jong PE, Hillege HL, Bakker SJ, de Zeeuw D.

Am J Kidney Dis. 2012 Nov;60(5):804-11. doi: 10.1053/j.ajkd.2012.06.017. Epub 2012 Jul 25.

PMID:
22835901
33.

Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance.

Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, Franssen CF.

Clin J Am Soc Nephrol. 2012 Oct;7(10):1615-23. doi: 10.2215/CJN.00850112. Epub 2012 Jul 19.

34.

Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population.

Brouwers FP, de Boer RA, van der Harst P, Struck J, de Jong PE, de Zeeuw D, Gans RO, Gansevoort RT, Hillege HL, van Gilst WH, Bakker SJ.

Heart. 2012 Sep;98(18):1348-53. doi: 10.1136/heartjnl-2012-302390. Epub 2012 Jul 21.

PMID:
22821276
35.

Short-term change in kidney function and risk of end-stage renal disease.

Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR.

Nephrol Dial Transplant. 2012 Oct;27(10):3835-43. doi: 10.1093/ndt/gfs263. Epub 2012 Jul 3.

PMID:
22764191
36.

High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate.

Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT; PREVEND study group.

Eur Heart J. 2012 Sep;33(18):2272-81. Epub 2012 Jun 27.

PMID:
22740385
37.

Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension.

Forman JP, Scheven L, de Jong PE, Bakker SJ, Curhan GC, Gansevoort RT.

Circulation. 2012 Jun 26;125(25):3108-16. doi: 10.1161/CIRCULATIONAHA.112.096115. Epub 2012 Jun 18.

38.

One-year change in kidney function is associated with an increased mortality risk.

Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR.

Am J Nephrol. 2012;36(1):41-9. doi: 10.1159/000339289. Epub 2012 Jun 14.

PMID:
22699706
39.

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.

Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Nov;27(11):4131-7. doi: 10.1093/ndt/gfs070. Epub 2012 Apr 20.

PMID:
22523115
40.

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT.

Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19.

41.

Comparison of cardiac positron emission tomography perfusion defects during stress induced by hemodialysis versus adenosine.

Assa S, Dasselaar JJ, Slart RH, de Jong PE, Voors AA, Tio RA, Franssen CF.

Am J Kidney Dis. 2012 Jun;59(6):862-4. doi: 10.1053/j.ajkd.2012.01.018. Epub 2012 Mar 23.

PMID:
22445134
42.

Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events.

Carter CE, Gansevoort RT, Scheven L, Heerspink HJ, Shlipak MG, de Jong PE, Ix JH.

Clin J Am Soc Nephrol. 2012 Apr;7(4):595-603. doi: 10.2215/CJN.09300911. Epub 2012 Mar 1.

43.

Vasopressin release is enhanced by the Hemocontrol biofeedback system and could contribute to better haemodynamic stability during haemodialysis.

Ettema EM, Kuipers J, Groen H, Kema IP, Westerhuis R, de Jong PE, Franssen CF.

Nephrol Dial Transplant. 2012 Aug;27(8):3263-70. doi: 10.1093/ndt/gfr793. Epub 2012 Feb 7.

PMID:
22323529
44.

Do albuminuria and hs-CRP add to the International Diabetes Federation definition of the metabolic syndrome in predicting outcome?

van der Velde M, Bello AK, Brantsma AH, El Nahas M, Bakker SJ, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Jun;27(6):2275-83. doi: 10.1093/ndt/gfr634. Epub 2012 Jan 9.

PMID:
22231032
45.

External validation of the KORA S4/F4 prediction models for the risk of developing type 2 diabetes in older adults: the PREVEND study.

Abbasi A, Corpeleijn E, Peelen LM, Gansevoort RT, de Jong PE, Gans RO, Rathmann W, Kowall B, Meisinger C, Hillege HL, Stolk RP, Navis G, Beulens JW, Bakker SJ.

Eur J Epidemiol. 2012 Jan;27(1):47-52. doi: 10.1007/s10654-011-9648-4. Epub 2012 Jan 4.

PMID:
22215562
46.

Effect of frozen storage on urinary concentration of kidney damage markers.

Nauta FL, Bakker SJ, Lambers Heerspink H, de Zeeuw D, van Oeveren W, Bilo H, de Jong PE, Gansevoort RT.

Am J Kidney Dis. 2012 Apr;59(4):586-9. doi: 10.1053/j.ajkd.2011.11.025. Epub 2011 Dec 28. No abstract available.

PMID:
22206741
47.

Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.

van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D, Gans RO, Struck J, Bilo HJ, Gansevoort RT, Bakker SJ.

Clin Chem. 2012 Jan;58(1):293-7. doi: 10.1373/clinchem.2011.166348. Epub 2011 Sep 26.

48.

Exploration of the difference in incidence of renal replacement therapy in elderly patients in Flanders and the Netherlands--a comparison of referral policy.

Visser A, Sunaert P, Franssen CF, Van Biesen W, Reijneveld SA, Jager KJ, de Jong PE, Izaks GJ, Dijkstra GJ, Gansevoort RT.

Nephrol Dial Transplant. 2012 Jan;27(1):338-44. doi: 10.1093/ndt/gfr346. Epub 2011 Jul 15.

PMID:
21765050
49.

Development and validation of a general population renal risk score.

Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT; PREVEND Study Group.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1731-8. doi: 10.2215/CJN.08590910.

50.

Plasma procalcitonin and risk of type 2 diabetes in the general population.

Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ.

Diabetologia. 2011 Sep;54(9):2463-5. doi: 10.1007/s00125-011-2216-3. Epub 2011 Jun 15. No abstract available.

PMID:
21674177

Supplemental Content

Loading ...
Support Center